ATLANTA, Sept. 29, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announces that both its Chief Scientific Officer and its Chairman are to receive academic honors on September 26 and October 21, respectively.
On September 26, Chief Scientific Officer Harriet L. Robinson, PhD, was honored as a Distinguished Faculty Member by the Emory University Emeritus College. This is an association of Emory's retired faculty and administrative staff who have joined together to advance their intellectual interests, to serve the University, and their University colleagues. The honor is bestowed to individuals for outstanding accomplishments and service to the University and its community. Dr. Robinson was honored for her ongoing work on the development of an effective HIV/AIDS vaccine. She has tirelessly devoted her career to finding a way to prevent and potentially cure this disease.
On October 21, Chairman David A. Dodd will receive the Distinguished Alumni Achievement Award from Georgia State University. This award is bestowed annually to a graduate of the University in recognition of outstanding professional and personal achievements in any field of endeavor. Mr. Dodd is one of only two alumni to receive the award this year. During his career, Mr. Dodd was the CEO of a number of successful pharmaceutical companies including Solvay and Serologicals Corporation. More recently, he has been engaged in starting new businesses focused on vaccines. Throughout his career, he has been an active contributor of time and talent helping civic, industry, and economic growth organizations.
Robert T. McNally, PhD, President and CEO of GeoVax Labs, said, "We are proud to see Harriet and David being honored by the academic institutions with which they have been affiliated in the past. This recognition is well deserved."
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and involves 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
The Investor Relations Group
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
|SOURCE GeoVax Labs, Inc.|
Copyright©2010 PR Newswire.
All rights reserved